David Hovland
Conseiller Juridique Général chez ELEDON PHARMACEUTICALS, INC.
Profil
David Hovland is currently the Chief Regulatory Officer at Eledon Pharmaceuticals, Inc. Prior to this, he was the Senior Vice President-Global Regulatory Affairs at Urovant Sciences Ltd.
from 2018 to 2021.
He was also the Vice President-Global Regulatory Affairs at Allergan Ltd.
(Ireland) from 2015 to 2018.
Before that, he was the Director-Global Regulatory Affairs at Amgen, Inc. from 2006 to 2010.
He started his career as a Study Director at Allergan Ltd.
(Ireland) from 1999 to 2002.
Dr. Hovland holds a doctorate degree from the University of California, Los Angeles and an undergraduate degree from the University of California, Berkeley.
Postes actifs de David Hovland
Sociétés | Poste | Début |
---|---|---|
ELEDON PHARMACEUTICALS, INC. | Conseiller Juridique Général | 19/04/2021 |
Anciens postes connus de David Hovland
Sociétés | Poste | Fin |
---|---|---|
UROVANT SCIENCES LTD. | Conseiller Juridique Général | 01/04/2021 |
ALLERGAN PLC | Conseiller Juridique Général | 01/01/2018 |
AMGEN INC. | Conseiller Juridique Général | 01/01/2010 |
ALLERGAN PLC | Corporate Officer/Principal | 01/01/2002 |
Formation de David Hovland
University of California, Los Angeles | Doctorate Degree |
University of California, Berkeley | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
AMGEN INC. | Health Technology |
ELEDON PHARMACEUTICALS, INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Allergan Ltd. (Ireland)
Allergan Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland. | Health Technology |
Urovant Sciences Ltd.
Urovant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. Its pipeline includes Vibegron (RVT-901) and URO-902. The company was founded on January 27, 2016 and is headquartered in London, the United Kingdom. | Health Technology |